華領醫藥-B(02552.HK)盈喜:預期中期溢利約11.84億元
格隆匯7月28日丨華領醫藥-B(02552.HK)公告,集團預期,相較2024年同期的期內虧損約人民幣142.0百萬元,將於截至2025年6月30日止六個月錄得溢利約人民幣1,184.1百萬元。
謹此提述(i)公司於2025年4月24日刊發的2024年報「報告期後的重要事件」,當中載述於2025年1月1日終止與拜耳所訂立獨家推廣服務協議後,未攤銷合約負債人民幣1,243.5百萬元已撥回損益,並確認爲集團的收益及(ii)2024年報「業務及財務摘要」第二項,當中載述公司全面接管華堂寧在中國內地的商業化任務。就此,公司已聘請在中國具備逾20年糖尿病藥物商業化經驗的醫藥銷售負責人,由其帶領公司的銷售及市場工作。
除確認上述與拜耳現已終止的獨家推廣服務協議相關的餘下未攤銷合約負債外,預期溢利能力增加乃由於成功移交華堂寧在中國的商業化任務及生產效率改善令毛利率增加。截至2025年6月30日止六個月,華領醫藥共售出約1,764,000盒華堂寧,銷售淨額約爲人民幣217.4百萬元。於2024年同期,共售出約846,000盒華堂寧,銷售淨額約爲人民幣102.7百萬元。前述銷售淨額的差異反映,在每盒價格維持不變情況下,實現銷售額增長111.8%,證明商業化任務已順利移交,且煥發新的活力。預期截至2025年6月30日止六個月的毛利約爲人民幣117.8百萬元,而於2024年同期錄得毛利人民幣47.8百萬元。預期毛利大幅增加是由於銷售額增加及毛利率提升。公司將呈報毛利率由2024年同期的46.5%增加至截至2025年6月30日止六個月的約54.2%。此主要由於生產效率及產量提高導致單位生產成本相應下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.